Summary: New research finds that supplementing vasopressin in naturally low-social rhesus monkeys improves their social behavior and facial recognition without provoking aggression. These results support the idea that vasopressin deficiency can contribute to social difficulties similar to those seen in autism spectrum disorder (ASD) and point to a possible path for targeted therapies addressing core social challenges.
Monkeys treated with nebulized vasopressin became more responsive to affiliative signals and showed stronger memory for faces—skills that are often impaired in autism. The study suggests a promising direction for precision interventions that aim to restore specific social functions rather than only managing secondary symptoms.
Key Facts:
- Improved social behavior without increased aggression: Vasopressin boosted prosocial responses and face memory while not producing aggressive behavior.
- Biological relevance to ASD: Low-social rhesus monkeys display social impairments that parallel some characteristics of autism in humans.
- Potential therapeutic approach: Correcting vasopressin deficits could offer a targeted strategy for improving core social deficits in ASD.
Source: Florida Institute of Technology
For years, Catherine Talbot, an assistant professor of psychology at Florida Institute of Technology, has been studying social behavior in male rhesus monkeys to understand how naturally low-social individuals can model human social challenges, including autism.
Her latest study shows that restoring deficient vasopressin levels helped low-social monkeys become more affiliative and improved their ability to recognize faces, all without increasing aggression. This finding could influence the future direction of autism treatment research.
The Centers for Disease Control and Prevention currently estimates that about one in 36 children in the United States is diagnosed with autism spectrum disorder, up from one in 44 reported in 2018. While two FDA-approved medications exist, Talbot notes that they mainly treat secondary symptoms rather than the underlying social deficits. This raises a central question: what biological factors drive those core social difficulties?
Rhesus monkeys vary naturally in social behavior: some are highly social while others are low-social, showing weaker social cognition. This variation mirrors the wide range of social engagement seen in people—from very social individuals to those who avoid social interaction, including some people with ASD. Talbot’s research aims to link biological differences to these behavioral patterns.
In a study published in PNAS, Talbot and colleagues from Stanford, UC Davis and the California National Primate Research Center examined whether vasopressin, a hormone known to influence social behavior, could be used therapeutically to improve social cognition in a primate model relevant to autism.
Earlier work from this team had shown lower vasopressin levels in their low-social monkey model and in a subset of people with ASD. Prior studies in rodents indicated that increasing vasopressin could raise aggression, which prompted caution about using the hormone clinically. Talbot points out, however, that aggression observed in those studies often occurred in contexts where an aggressive response is species-typical—such as defending territory or mates—and that those studies used neurotypical animals rather than individuals with naturally low vasopressin levels.
“Individuals with the lowest vasopressin levels may be the ones who benefit most; that idea supports a precision medicine approach,” Talbot said.
In the reported experiments, the team focused on low-social male rhesus monkeys that had low cerebrospinal fluid vasopressin and displayed many autism-like traits. The researchers delivered vasopressin via a nebulizer, a voluntary method the monkeys could choose to use. For a few minutes each week, monkeys held their faces near the nebulizer and received the dose while drinking white grape juice, a treat they favored.
After confirming that nebulized vasopressin raised central nervous system vasopressin levels, the investigators evaluated how the monkeys reacted to social and nonsocial cues. They showed videos of affiliative and aggressive behavior and tested recognition memory for faces and objects—an important component of social cognition.
Under placebo conditions, low-social monkeys showed limited responses to social communication and were better at remembering objects than faces, a pattern similar to some people with autism. Following vasopressin treatment, these monkeys began to reciprocate affiliative signals with typical prosocial behaviors, while aggressive responses did not increase. Vasopressin also enhanced face recognition memory, bringing it in line with their object recognition performance.
In short, vasopressin “rescued” key aspects of social cognition in low-social monkeys: it selectively improved affiliative responding and facial memory without producing aggression. The authors describe these outcomes as evidence that vasopressin supplementation can restore species-typical social responses in individuals with naturally low vasopressin signaling.
Talbot called the results exciting after years of work and numerous challenges. One co-author on the study has already begun pilot work translating these findings to small cohorts of people with autism, and Talbot expects additional clinical trials to follow.
Next steps in her lab include examining more complex social cognitive abilities—such as theory of mind, or perspective-taking—to see how these functions differ between low-social and more social monkeys and how those differences map to biology. In the longer term, the team aims to test whether early intervention with vasopressin in at-risk young monkeys can alter developmental trajectories, with the goal of informing targeted human trials.
About this Autism and social neuroscience research news
Author: Madeline Taylor
Source: Florida Institute of Technology
Contact: Madeline Taylor – Florida Institute of Technology
Image: The image is credited to Neuroscience News
Original Research: Closed access.
“Nebulized vasopressin penetrates CSF and improves social cognition without inducing aggression in a rhesus monkey model of autism” by Catherine F. Talbot et al. PNAS
Abstract
Nebulized vasopressin penetrates CSF and improves social cognition without inducing aggression in a rhesus monkey model of autism
Low cerebrospinal fluid (CSF) arginine vasopressin (AVP) concentration serves as a biomarker linked to social impairment in low-social monkeys and in some children with autism. These observations led the authors to test whether AVP administration can improve social functioning in a primate model relevant to ASD.
Although AVP can increase aggression in neurotypical animals with intact AVP systems, this study evaluated effects in naturally low-social male rhesus monkeys with a high burden of autistic-like traits using a voluntary nebulized delivery method.
Monkeys received nebulized AVP or placebo in a within-subjects design. Study 1 (N = 8) assessed social cognition across two tasks comparing social versus nonsocial stimuli. In Test 1, placebo-treated monkeys lacked face recognition memory, whereas AVP treatment restored face recognition. Object recognition remained intact and unchanged across conditions. In Test 2, placebo-treated monkeys did not respond to conspecific social communication cues; after AVP treatment, they reciprocated affiliative cues with species-typical affiliative responses. Crucially, AVP did not elevate aggressive responses to aggressive or affiliative social signals.
Study 2 (N = 4) examined pharmacokinetics of the nebulized administration. After AVP nebulization, cisternal CSF AVP levels rose linearly, while blood AVP showed a quadratic rise-and-fall pattern. These results indicate that nebulized AVP likely reaches the central nervous system, selectively promotes species-typical social responses in low-social individuals, and does so without inducing aggression.
The authors conclude that nebulized AVP may hold therapeutic promise for treating similar social symptoms in people with autism, particularly in very young or lower-functioning individuals, and support further clinical evaluation of targeted, biology-driven interventions for core social deficits.